Novo’s share price fell 8 per cent on Monday, having previously dived in December after a late-stage trial of CagriSema in overweight or obese people without diabetes found they lost an average of ...

Novo Nordisk has acknowledged that the first phase 3 readout for new obesity hopeful CagriSema was hard to interpret and disappointed investors, but it has a plan to revitalise the programme.

Novo Nordisk shares have dropped significantly in December due to disappointing CagriSema trial results, but not everything from those results was negative. Amycretin's promising early-stage ...

Novo Nordisk's latest trial results for CagriSema, their obesity drug candidate, show it as a successor to their blockbuster Wegovy, but not superior to Eli Lilly's Mounjaro. This has led to ...

LONDON/COPENHAGEN (Reuters) -Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data published in December that disappointed ...

Less-than-stellar phase 3 results with Novo Nordisk's highly anticipated obesity therapy CagriSema have caused its shares to fall by over a fifth, wiping around $94 billion off its market cap.

Wegovy's potential successor, CagriSema, came up short of investor expectations in a closely watched Phase 3 trial. Novo's stock has fallen more than 20% over the last year, and people feared ...

The next generation of weight-loss drugs aim to help patients lose more weight even faster. CagriSema — developed by Novo Nordisk, the company behind Wegovy — is one example. In a trial last ...

The trial showed that patients treated with CagriSema exhibited weight loss of 22.7% after 68 weeks, well short of Novo's targeted expectation of at least 25% weight loss. The press release ...